Annual Report 2017 of Central Pharmaceuticals Limited

It is a broadly described annual report of Central Pharmaceuticals Limited in the year of 2017. During the year under report, The Company’s cost of goods sold was Tk. 234.50 million (51.55% of sales) as compared to last year’s cost of goods sold of Tk. 221.54 million 60.76% of sales). Gross Profit earned during the year was Tk. 220.78 million as against last year’s gross profit of Tk. 205.18 million. The company earned the net profit during the year amounting to Tk. 109.09 million as compared to last year’s net profit of Tk. 97.78 million. During the year, there is an interest gain (other income) of Tk. 7,375 compared to last year other income Tk. 6,186.

The board of directors has recommended @10% stock dividend for the shareholders out of accumulated profit for the year ended 30 June, 2017 (subject to the approval in the forthcoming AGM) whose names will appear in the share register of the Company and/or depository register of CDBL as on record date i.e. 30 November, 2017. The bonus issue will raise the paid-up capital up to Tk. 1140.95 million (paid-up capital before the bonus is Tk. 1037.23 million). These financial statements are presented in Bangladesh Taka (Taka/Tk/BDT) which is the company’s functional currency. All financial information presented in Taka has been rounded off to the nearest Taka.

More Annual Report of Central Pharmaceuticals Limited:

  1. Annual Report 2014 of Central Pharmaceuticals Limited
  2. Auditor’s Report 2015 of Central Pharmaceuticals Limited
  3. Annual Report 2016 of Central Pharmaceuticals Limited
  4. Annual Report 2017 of Central Pharmaceuticals Limited